Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy.

ABSTRACT: Cancer immunotherapy requires a specific antitumor CD8⁺ T cell-driven immune response; however, upon genetic and epigenetic alterations of the antigen processing and presenting components, cancer cells escape the CD8⁺ T cell recognition. As a result, poorly immunogenic tumors are refractory to conventional immunotherapy. In this context, the use of viral cancer vaccines in combination with hypomethylating agents represents a promising strategy to prevent cancer from escaping immune system recognition. In this study, we evaluated the sensitivity of melanoma (B16-expressing ovalbumin) and metastatic triple-negative breast cancer (4T1) cell lines to FDA-approved low-dose decitabine in combination with PeptiCRAd, an adenoviral anticancer vaccine. The two models showed dif

SUBMITTER: Russo S 

PROVIDER: S-EPMC10869747 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature